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ABSTRACT 2 
Background 3 
Despite the introduction of 21st century surgical and neoadjuvant treatment modalities, survival 4 
of osteosarcoma (OS) patients has not improved in the last decades. Advances will depend in 5 
part on the development of clinically relevant and reliable animal models. This study 6 
describes the engineering and validation of a humanized tissue engineered bone organ 7 
(hTEBO) for preclinical research on primary bone tumors in order to minimize false positive 8 
results due to interspecies differences in xenograft models. 9 
Methods 10 
Pelvic bone and marrow fragments were harvested from patients when reaming the acetabular 11 
ground during hip arthroplasty. HTEBOs were engineered by embedding fragments in a fibrin 12 
matrix containing bone morphogenetic protein 7 (BMP-7) and implanted into NOD-scid mice. 13 
After ten weeks of subcutaneous growth, one group of hTEBOs was harvested to analyze the 14 
degree of humanization. A second group was injected with human luciferase-labelled OS cells 15 
(Luc-SAOS-2) and compared to tumors raised via intratibial injection. Tumor growth was 16 
followed in vivo via bioluminescence imaging. After 5 weeks osteosarcomas were harvested 17 
and analyzed. 18 
Results 19 
After 10 weeks of in vivo growth a new bone organ developed, containing human bone matrix 20 
as well as viable and functional human hematopoietic cells. Five weeks after injection of Luc-21 
SAOS-2 cells into this humanized bone microenvironment, spontaneous metastatic spread to 22 
the lung was evident. Relevant prognostic markers like VEGF and periostin were found in this 23 
humanized OS but not in the conventional intratibial OS model. Hypoxia-inducible 24 
transcription factor 2α (HIF-2α) was detected only in the humanized OS. 25 
Conclusions 26 
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We report an in vivo model that contains human bone matrix and marrow components in one 27 
organ. BMP-7 made it possible to maintain viable mesenchymal and hematopoietic stem cells 28 
and created a bone microenvironment close to the human physiology.  29 
Clinical Relevance 30 
This novel platform enables preclinical research on primary bone tumors in order to test new 31 
treatment options.  32 
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INTRODUCTION  33 
The survival of osteosarcoma (OS) patients has not significantly improved in the past 20 years, 34 
although the interplay between chemotherapy and surgical intervention has been continuously 35 
modified1, 2. While new surgical techniques have led to an increase in quality of life and better 36 
local tumor control3-5, metastases remain the major cause of death and are present in 12.4% of 37 
patients at the time of diagnosis. Only 26.7% of these patients survive longer than 10 years6, 7.  38 
The hampered efforts to increase survival rates of OS patients are due in part to a lack of 39 
clinically relevant animal models that can be used to reliably identify novel therapeutic agents. 40 
De facto, 80% of all substances that proved to be effective in preclinical testing, failed when 41 
finally trialed in humans8-11. This is mainly due to species-specific incompatibilities in 42 
intercellular communication and intracellular signaling pathways12.  43 
An ideal OS animal model should replicate all aspects of the human disease, specifically with 44 
regards to tumor biology, marker expression and response to therapeutic agents. As the 45 
prognosis of OS patients is significantly influenced by the presence of lung metastasis, it is a 46 
conditio sine qua non for an in vivo model to mimic the spontaneous development of pulmonary 47 
metastases13. 48 
Additionally, several studies have highlighted the importance of the tumor microenvironment 49 
for the initiation, progression and metastatic spread of solid tumors. Berlin et al. demonstrated 50 
that the human KRIB OS cell line only forms metastases in mice when injected into the mouse 51 
bone but not when inoculated subcutaneously14. Cells such as mesenchymal and hematopoietic 52 
stem cells (MSCs and HSCs), both residing in the bone microenvironment, have a considerable 53 
impact on tumor development and metastasis15-20. Disseminated cancer cells directly compete 54 
with HSCs for occupancy of their niche and changes of the HSC microenvironment alter cancer 55 
cell dissemination21. Additionally, other cell types such as macrophages, present in bone and 56 
tumors, have been shown to be of prognostic significance in OS patients22.  57 
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Humanized xenograft models of osteotropic tumors that incorporate not only human 58 
extracellular bone matrix but also cellular components of the human microenvironment have 59 
emerged in recent years23, 24. However, humanizing in vivo approaches for research on primary 60 
bone tumors have been neglected and failed to consider the importance of the hematopoietic 61 
niche. To our knowledge, we are the first to have developed and validated an animal model 62 
that utilizes recombinant human bone morphogenetic protein 7 (rhBMP-7) in combination with 63 
human pelvic bone and mimics the clinical aspects typically seen in OS patients. 64 
 65 
METHODS 66 
Animal housing and handling. 67 
All animal studies were conducted in accordance with the Australian Code of Practice for the 68 
Care and Use of Animals and approved by the Animal Ethics Committee of *** Blinded by 69 
JBJS ***. Twenty four 4-week old male NOD-scid mice were purchased from the Animal 70 
Resources Centre (Canning Vale, WA, Australia). 71 
 72 
Engineering of a humanized tissue-engineered bone organ (hTEBO) 73 
Cancellous bone with marrow was obtained during reaming the acetabulum from 3 different 74 
otherwise healthy human donors undergoing hip arthroplasty as approved by the ethics 75 
committees of *** Blinded by JBJS *** under informed consent and in accordance with the 76 
World Medical Association’s Declaration of Helsinki. The first two reamer heads were 77 
discarded to minimize the amount of cartilage remnants and cortical bone within the samples. 78 
The material was then positioned in a plastic cylinder (volume 0.5 cm3). RhBMP-7 (30 µL in 79 
1 µg/µL, Olympus Biotech, USA) was embedded into 60 μL of fibrin glue (TISSEEL Fibrin 80 
Sealant, Baxter Healthcare International) and added to the graft material (Fig. 1). Constructs 81 
were subcutaneously implanted at the left and right flank of 18 mice as previously 82 
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described23. Post implantation, hTEBOs were allowed to form a bone organ for 10 weeks. Six 83 
of the 18 animals were then euthanized via CO2 asphyxiation in order to characterize the 84 
morphology and cellular composition of hTEBOs via µCT, histology, immunohistochemistry 85 
and flow cytometry.  86 
 87 
SAOS-2 cell culture 88 
The human SAOS-2 cell line (Sigma-Aldrich, Castle Hill, NSW, Australia) was chosen to 89 
establish OS growth25, 26. To assess tumor spread by bioluminescence imaging (BLI), 90 
luciferase-expressing human SAOS-2 cells (Luc-SAOS-2) were generated using a lentiviral 91 
gene expression system (Invitrogen, Mulgrave, Victoria, Australia) according to the 92 
manufacturer’s instructions using blasticidine (Invitrogen) selection (5 µg/mL). Standard 93 
culture was performed with McCoy’s 5A modified media (Gibco, Life Technologies, 94 
Mulgrave, Victoria, Australia). 95 
 96 
Development of a humanized OS platform 97 
5x105 Luc-SAOS-2 cells in 50 µL PBS were transcutaneally injected into hTEBOs of mice 98 
(n = 12) using inhalational anesthesia with isoflurane. Correct injection was verified via 99 
radiographic and BLI control. To compare humanized OS growth with the conventional 100 
murine OS xenograft model, the same amount of Luc-SAOS-2 cells was inoculated intratibially 101 
in 6 mice27. Bioluminescent imaging (BLI) was performed weekly to assess in vivo tumor 102 
growth and metastatic spread. After 5 weeks mice were sacrificed and hTEBOs as well as 103 
visceral organs were excised for ex vivo BLI and further tumor analysis.  104 
Bioluminescence Imaging 105 
For weekly BLI (IVIS Spectrum 200, Perkin Elmer, USA) animals were imaged 15 min post 106 
i.p. injection of 100 µL (7.5 mg/mL) luciferin (PerkinElmer, USA). Ex vivo BLI was performed 107 
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20 min after luciferin injection to determine metastatic tumor burden of visceral organs. Images 108 
were analyzed with the Living Image Software (Perkin Elmer) using a threshold set at 10% 109 
around each bioluminescent source to determine the amount of photons emitted within a given 110 
time. Results were evaluated as average radiance [p/s/cm²/sr] ± SEM (standard error of the 111 
mean)23,24. 112 
 113 
Micro-computed tomography (μCT) 114 
The hTEBOs were analyzed with a high-resolution μCT scanner (μCT 40, Scanco Medical AG, 115 
Switzerland) and scanned at a voxel size of 16 μm. Samples were evaluated at a threshold of 116 
150, a filter width of 0.8 and a filter support of 1.  117 
 118 
Flow cytometry 119 
For flow cytometry, ossicles were gently crushed with a mortar in ice-cold PBS with 2% FCS 120 
and then filtered on a 40 μm cell strainer. Analyses of the murine hematopoietic system was 121 
performed as previously described28. Aliquots of 5 x 106 bone marrow cells were stained with 122 
huCD45-APCCy7 (Biolegend, Karrinyup, Western Australia), mouse CD45-biotin 123 
(Biolegend), huCD34 APC (Biolegend,), huCD19-PE (Biolegend), huCD20PE (Biolegend), 124 
huCD14-PeCy7 (Biolegend) and huCD3-V450 (BD Bioscience, North Ryde, New South 125 
Wales, Australia) and streptavidin brilliant violet 605 (Biolegend). Analysis was gated on 126 
viable cells following exclusion of dead cells with 7-amino actinomycin D (Life Technologies). 127 
 128 
Histology and Immunohistochemistry 129 
Fixed samples were decalcified and stained for immunohistochemical analysis using our a 130 
standard protocol23,24. Sections were incubated with the primary antibody solutions 131 
according to Appendix Table 1. In order to detect human extracellular matrix sections 132 
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were stained for human specific (hs) collagen I (hsCol-I) and Osteocalcin (OC). Human 133 
cells were detected by staining for nuclear mitotic apparatus protein 1 (hsNuMa). Human 134 
MSCs were stained for hsCD146 and human leucocytes for hsCD45. Proliferating tumor 135 
cell were detected by staining for Ki67. Proteins under current investigation for their 136 
application as OS tumor markers are vascular endothelial growth factor (VEGF), 137 
hypoxia-inducible transcription factor 1α (HIF-1α) and periostin. Sections were also 138 
stained for hypoxia-inducible transcription factor 2α (HIF-2α) as this protein plays an 139 
important role in tumor cell proliferation and metastasis31,33,50-55. Human bone and OS 140 
tissue as well as mouse bone sections were used as positive and negative controls, 141 
respectively. The use of human OS tissue was approved by the Ethics Committee of the 142 
University of Regensburg, Germany (Approval No: 12-101-0013). Tartrate resistant acid 143 
phosphatase (TRAP) staining for osteoclasts has been performed according to our standard 144 
protocol23. 145 
 146 
Statistical analysis 147 
IBM SPSS Statistics (version 21) was used for statistical analysis. Data was tested using the 148 
student t-test and Mann-Whitney-U test to evaluate differences between groups. The level of 149 
significance was set at p < 0.05. 150 
 151 
Source of funding 152 
*** Blinded by JBJS *** 153 
 154 
RESULTS 155 
Tissue engineering of vital humanized bone  156 
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Ten weeks post implantation hTEBOs developed calcified ossicles that appeared to be of 157 
hard structure and rich in blood (Fig. 2). µCT and morphological H&E analysis 158 
demonstrated a trabecular network surrounded by an outer cortex-like structure. Viable 159 
osteocytes were found residing in the bone lacunae. Trabecular spaces were filled with 160 
hematopoietic cell clusters of different lineages. 161 
 162 
Human bone marrow elements can be maintained in hTEBOs 163 
Immunohistochemical staining revealed cells positive for human specific (hs) CD146 and 164 
identified as MSCs mainly located in direct proximity to sinusoids (Fig. 2). Furthermore, we 165 
identified human CD45+ leucocytes. Flow cytometry verified these findings and revealed that 166 
cells equivalent to human HSCs (hsCD34) can survive within the humanized 167 
microenvironment. Adding rhBMP-7 led to a distribution of bone marrow cells 168 
morphologically equivalent to those in corresponding mouse femurs (Appendix Fig. 1). Human 169 
B cells, T cells and monocytes were also present. Omitting rhBMP-7 led to bone constructs 170 
with non-viable matrix without human and hardly any murine bone marrow cells. 171 
 172 
Direct cell injection into hTEBOs results in reproducible local and metastatic OS growth 173 
Luc-SAOS-2 cells were injected directly into the newly formed humanized bone organs (Fig. 174 
3). Positive BLI tumor signals within the hTEBC were found in 91.7 % of the mice (11/12) 175 
after 5 weeks. Ex vivo BLI indicated metastatic spread to the lung in 72.7% (8/11) at this 176 
experimental endpoint (Fig. 4). µCT depicted osteoblastic regions within the hTEBOs, 177 
indicating the localization of a tumor (Fig. 3). Histology showed neoplastic tissue with a high 178 
amount of extracellular matrix (ECM) in these regions as indicated by the presence of hsCol-I 179 
and tumor osteoid, the latter being pathognomonic for OS. These areas were accompanied by 180 
regions of high cellular density and high proliferative activity as depicted by Ki67 staining. 181 
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Staining for hsNuMa proved that tumor cells were indeed of human origin. The overall 182 
histomorphological appearance was similar to patients with an osteoblastic subtype of OS.  183 
H&E staining of lung tissue demonstrated metastases with human osteoid as shown by the 184 
presence of eosinophilic extracellular deposits (Fig. 4). Metastases were positive for Ki67 and 185 
hsNuMa, demonstrating that the lung lesions were proliferating and of human origin.  186 
 187 
Prognostic markers are expressed at the primary and secondary tumor site 188 
Immunohistochemical staining for clinical relevant prognostic markers proved the presence of 189 
HIF-2α in regions within the humanized tumors where high levels of VEGF expression 190 
coexiste30-34 (Fig. 5). HIF-1α was variably expressed (n = 2 of 5 analyzed samples). Staining 191 
for periostin was positive in the primary humanized tumor. Equivalent staining of an OS 192 
patient sample showed the same expression pattern for HIF-2α, VEGF and periostin. 193 
 194 
Intratibial tumor growth depicts different OS patterns  195 
To compare the humanized OS model with the conventional model, Luc-SAOS-2 cells were 196 
injected into the left tibia (Fig. 6). µCT analyses demonstrated an exophytic growing tumor 197 
located at the proximal tibia. Immunohistochemical analysis showed positive staining for 198 
hsCol-I and hsNuMA. These cells were again highly proliferative as shown by Ki67 staining. 199 
Assessing the histological tumor morphology, intratibial tumors appeared more homogeneous 200 
with less osteoid-rich areas than the humanized OS and the OS found in patients (Fig. 3). 201 
Additionally, cell nuclei and cell shape appeared more spherical and uniform. 202 
After 5 weeks, a positive BLI signal was detected within the tibia of 50% of mice (n = 3/6). To 203 
compare the metastatic load of the lungs after 5 weeks, the average radiance of both groups 204 
was calculated via in vivo BLI. Although the average radiance was doubled in the hTEBO 205 
group (4.00x103 ± 0.40x103 SEM [p/s/cm²/sr]) in comparison to the intratibial group (2.04x103 206 
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± 1.82 x103 SEM [p/s/cm²/sr]), this difference was not significant (p = 0.648). Staining for 207 
HIF-2α, VEGF and periostin was negative in the analyzed intratibial OS samples (Fig. 5). 208 
 209 
DISCUSSION 210 
In the last decades, efforts to reduce the mortality rate in OS have remained disappointing as 211 
most novel therapeutic concepts have failed 8, 9. This might be in part due to the fact that 212 
conventional xenograft mouse models might produce false positive or negative results as 213 
functional species-specific cross-reactivity exists between inoculated human tumor cells 214 
and the murine host12, 35. Researchers have only recently started to realize the relevance 215 
of tissue microenvironments and the importance of extracellular structural cues for 216 
tumor development23, 36, 37. Humanizing animal models addresses both concerns by engrafting 217 
human tissues into immune-compromized mice prior to transplantation of human tumor cells 218 
and has been shown to provide a favorable microenvironment, in particular if focusing on 219 
aspects of the metastatic cascade24, 38.  220 
In the past, attempts to humanize bone organs within mice by implanting human bone 221 
fragments without any growth factor support have failed as they did not recapitulate the 222 
morphological and functional features of a human organ bone (Appendix Fig. 1)39-41. 223 
Therefore, we decided to utilize human cancellous bone in combination with rhBMP-7. 224 
Additionally, we did not use bone from the femur as described by others, but from the pelvis, 225 
which contains more red proliferative bone marrow and adult stem cell fractions42. This bone 226 
can be easily obtained from patients undergoing hip replacement during the reaming of the 227 
acetabular fossa. We demonstrated that human MSC and HSC populations were able to survive 228 
for at least 10 weeks and portrayed a humanized bone marrow compartment. Most humanized 229 
mouse models, which aim for a replacement of the mouse bone marrow have been 230 
accomplished by injection or implantation of human hematopoietic tissues12, 43. Although these 231 
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techniques are able to create a higher level of humanization of the hematopoietic system, they 232 
fail to provide a peripheral hematopoietic bone organ that can provide species-specific factors 233 
necessary for the maintenance of human HSCs and progenitor cells. The essential agent driving 234 
the development and maintenance of this fully functional bone organ is rhBMP-723, 44. Only 235 
recently, a small number of other groups have begun to hypothesize concerning the relevant 236 
role of BMP-7 in hematopoiesis45-48. Our study represents the in vivo validation of this work. 237 
 238 
After the initial steps of characterization, we hypothesized that this model is highly suitable to 239 
study primary bone tumor growth and metastasis. We found a higher tumor take rate as well 240 
as a high rate of metastatic dissemination in our hTEBO carrying mice than in the animals with 241 
conventional intratibial OS. Metastatic tumor load was not significantly different between 242 
the groups, which might be the result of low sample size. This and the utilization of one 243 
single cell line - not consistently described as a metastatic cell line – can be seen as a 244 
limitation of the study. Nevertheless, the finding of a high metastatic potential in the 245 
humanized OS is of utmost importance, for the clinical relevance of an OS model6, 13. 246 
OS is characterized as a mesenchymal malignancy producing tumor osteoid, the sole 247 
pathognomonic marker for OS to date. Histological analyses of the tumors grown in hTEBOs 248 
clearly met the histopathological criteria for the diagnosis of OS49. The inoculated human OS 249 
cells showed extensive production of human ECM proteins a growth pattern characterizing the 250 
most common osteoblastic OS subtype. Intratibial tumors mimicked a different OS 251 
morphology, most likely a small cell subtype 49. Similar histomorphological aspects can be 252 
found in studies describing intratibial injection of OS cell lines performed by Berlin et al. 253 
utilizing of  KRIB cells and Dass et al. using SAOS-2 cells 14,59. 254 
To underline the clinical relevance of our model, we have studied the prognostic marker 255 
expression of the tumors. VEGF has been shown to be regularly expressed in OS patients 256 
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although its use as a prognostic marker is under debate50, 51. We were able to find a high 257 
expression of VEGF in the humanized tumors, but not in the intratibial ones. This positive 258 
expression was accompanied by positive staining for HIF-2α, which was also not present in 259 
the intratibial tumors. As far as we know, we are the first to describe an upregulation of HIF-260 
2α in OS and also could verify its presence in a patient sample.  HIF-2α has been shown to 261 
drive angiogenesis and proliferation as well as tumor metastasis on the basis of chronic 262 
hypoxia33, 52-55. Although we have stained tumor tissue from only one OS patient, this 263 
protein might represent a new prognostic marker as well as a therapeutic target as it has been 264 
shown in other studies that this protein plays a pivotal role in tumor development52. 265 
Additionally, we could prove the presence of periostin within the humanized OS. High 266 
expression of periostin has been linked to a poor prognosis in OS patients mainly due to a 267 
higher rate of metastasis31. Again, periostin was not detected in intratibial OS. These findings 268 
underline the clinical relevance of our novel preclinical model, not only through their ability 269 
to reflect the histological appearance, but also the molecular marker expression of human 270 
lesions. 271 
 272 
Our humanized bone microenvironment provides an advantage over the conventional animal 273 
models as new therapeutic options are targeted against the tumor cells as well as interfere with 274 
the interactions between tumor cells and their microenvironment. Recently, the modulation of 275 
natural killer cell or macrophage function through Cetuximab or muramyl tripeptide 276 
phoshatidylethanolamine (MTPE) has been shown to have potential efficacy against primary 277 
OS as these cell types typically reside within the bone and tumor microenvironment56, 57. 278 
However, preclinical assessment of new drugs might incorrectly be interpreted as non-valuable 279 
because they are specifically directed against human cells, proteins or genes. For example, 280 
Denosumab is an antibody that inhibits bone resorption when binding to the human, but not 281 
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the murine, receptor activator NF-κB Ligand (RANKL)58. It now can be investigated in a 282 
preclinical animal model.  Hence, for the first time species-specific considerations can be 283 
addressed in primary bone tumor research.   284 
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Figure Legends 485 
Figure 1: Experimental outline and differences between the presented and conventional tissue 486 
engineering approaches. We utilized a top-down approach by harvesting the acetabular 487 
reaming material from patients undergoing hip arthroplasty (A [i]). The first reaming portion 488 
was discarded in order to minimize the amount of cartilage and to achieve a high proportion of 489 
blood marrow (A [ii]& [iii]).  The material was then positioned in a plastic cylinder. Then, 490 
rhBMP-7 was embedded into fibrin glue and added to the graft material (A [iv]). These grafts 491 
were subcutaneously implanted at the left and right flank of NOD-scid mice (A [v]). HTEBOs 492 
were allowed to form a humanized organ for 10 weeks. One group of mice was then euthanized 493 
and ossicles were harvested for bone matrix and marrow analysis (A [vi]); another group was 494 
injected with Luc-SAOS-2 cells (A [vii]). HTEBOs with tumors were harvested after additional 495 
5 weeks for further analysis (A [viii]). Bottom-up approaches (B) relate to methods that 496 
generate tissues by scaffold printing (B [i]), cell isolation from humans (B [ii]), in vitro cell 497 
culture and cell differentiation (B [iii]) before implantation (B [iv]). Therefore, these 498 
techniques are dependent on time consuming bench work processes and significantly depend 499 
on host- and donor-derived stem cells, which organize and replace tissues during engraftment. 500 
Figure 2. Establishment of a humanized tissue-engineered bone organ (hTEBO). After 10 501 
weeks of subcutaneous in vivo growth in NOD-scid mice, ossicles (A) with trabecular 502 
formations and an outer cortex-like structure have formed as seen in µCT (B) and H&E staining 503 
(C), the latter showing a viable bone marrow compartment (n=6 of 6 samples). Viable 504 
osteocytes were still residing within the lacunae (D, ) and bone formation was still ongoing 505 
as depicted by staining for human osteocalcin (OC, antibody not reactive to mouse; n=6/6). 506 
Immunohistochemistry using human-specific (hs) antibodies showed hsCD146+ cells located 507 
in direct proximity to sinusoids and therefore were identified as MSCs (E, ; n=6/6). Anti-508 
hsCD45 is a panleukocytic antibody and stained in particular parasinusoidal cells (F, ; 509 
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n=6/6). Flow cytometric analysis of 2 ossicles (G) verified the presence of human HSCs by 510 
staining for hsCD34 and hsCD45 after excluding murine cells with muCD45. Tr, trabeculae; 511 
Cx, Cortex; BM, bone marrow; 512 
Figure 3.  Establishment of a humanized tissue-engineered OS model. Five weeks after 513 
injection of Luc-SAOS-2 cells into hTEBO (A) 91.7 % of the mice showed tumor take as 514 
verified by BLI (B). µCT showed a mainly osteoblastic tumor formation (C, ), which was 515 
identified as a neoplasm producing human collagen-I depicted by immunohistochemistry (G, 516 
; n=6/6). H&E staining showed areas with extensive ECM formation (D) next to tumor 517 
regions of high cell density (*) with areas of osteoid (). The areas with high cellularity 518 
showed an increased proliferation as depicted by Ki67 staining (E; n=6/6) and cells within 519 
these areas were shown to be human as verified by positive hsNuMA staining (F; n=6/6). 520 
The tissue morphology of humanized OS (D&G) looked similar to the histological appearance 521 
of a human osteosarcoma (H&I). 522 
Figure 4. Evaluation of the metastatic potential of the model. Lung metastasis originating from 523 
humanized OS showed the production of osteoid (A, ). Cells within the lesion proved to be 524 
human when stained for hsNuMA (B), therefore identifying these as an OS metastasis. Ex vivo 525 
BLI analysis of harvested lungs (C) determined lung metastasis in 72.7% of mice after 5 weeks 526 
(8/11 mice). Scale bars depict 100µm. 527 
Figure 5. Evaluation of marker expression. Immunohistochemical staining showed islets with 528 
an increased expression of VEGF (A; n=4/5) accompanied by a high expression of HIF-2α (D; 529 
n=4/5). Periostin was detected in humanized OS (G; n=4/5). Intratibial tumors were all 530 
negative for these markers (C,F,I; n=0/3) in comparison to the humanized OS and an OS 531 
patient sample (B,E,H). Scale bars depict 100µm.  532 
Figure 6. Comparison to the conventional intratibial mouse model. Intratibial injections of 533 
Luc-SAOS-2 cells were performed under radiographic control (A). µCT revealed an 534 
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exophytic growing tumor (B), which also produced human-specific ECM as shown by positive 535 
staining for hsCol-I (C). The cells also proved to be of human origin (E) and were proliferating 536 
(F). The tissue morphology of intratibial OS (D) showed less osteoid formation and a more 537 
homogeneous growth pattern than humanized OS (Figure 3D). BLI showed a tumor take 538 
rate of 50 % (3/6 mice, G). Although the means of the average radiances of lung metastasis 539 
were doubled in the humanized OS group compared to animals with intratibial tumors, this 540 
difference was not significant (p = 0.648) (H). 541 
 542 
Appendix Figure 1: Morphological evaluation of human bone marrow cell fractions. The 543 
fractions of human blood marrow cells within the hTEBOs without (A&B) and with rhBMP-7 544 
(C&D) were analyzed after 10 weeks of in vivo growth. H&E stainings of the hTEBO with 545 
rhBMP-7 (C&D) and the mouse femur (E&F) suggested equal bone marrow cell morphology, 546 
whereas hTEBOs, growing without rhBMP-7 were only filled with fibrous and adipose tissue 547 
(A&B). Flow cytometric analysis was performed in 2 hTEBOs without rhBMP-7 (Panel G) 548 
and 2 with rhBMP-7 (Panel H). Human (hu) CD45+ leucocytic cells (G&H [i]) and huCD34+ 549 
HSCs (G&H [ii]) were only present in the rhBMP-7 ossicles (H [i]&[ii]). HuCD3+ T cells and 550 
huCD19+/CD20+ B cells as well as huCD14+ monocytes also were only detected within the 551 
hTEBOs with added rhBMP-7 (H [ii]&[iii]). Graphs show results of representative hTEBOs. 552 
Tr, trabeculae; Cx, cortex; BM, bone marrow;  GP, growth plate; FT, fibrous tissue. 553 
